Skip to main content

Table 1 Patient characteristics (n = 204)

From: A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin

Age

 

 Median, year

61

 Range, year

18-92

Gender

 

 Male, n(%)

123 (60.3)

 Female , n(%)

81 (39.7)

Median CLcra, mL/min

88.7

NPb origin

 

 Cancer related NP, n(%)

55 (27.0)

 Chemotherapy related NP, n(%)

24 (11.7)

 Non-cancer related NP, n(%)

125 (61.3)

Regular strong opioid

 

 yes, n(%)

36 (17.6)

  -fentanyl, n

17

  -oxycodone, n

16

  -morphine, n

3

Median dosec (range), mg/day

60 (15–300)

 no, n(%)

168 (82.4)

Initial dose of pregabalin

 

 150 mg/day, n(%)

124 (60.8)

 75 mg/day, n(%)

73 (35.8)

 50 mg/day, n(%)

3 (1.5)

 25 mg/day, n(%)

4 (1.9)

  1. aCLcr: creatinine clearance using the Cockcroft-Gault equation
  2. bNP: neuropathic pain
  3. cconverted to oral morphine